HDAC6 and thyroid cancer: The utilization of a reversible ATP-competitive multikinase inhibitor small compound SP600125 on thyroid cancer cell lines leads to suppression of the ROCK/HDAC6 pathway and induction of cell death and senescence through the p53-p21 pathway.